PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Tuesday, Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804 in patients with moderately to severely active ulcerative colitis or Crohn's disease. In the DUET-CD study, JNJ-4804a demonstrated higher clinical remission rates and endoscopic response rates than golimumab...
Tuesday, Eli Lilly and Company (LLY) announced new long-term data from the LUCENT-3 open-label extension study in patients with moderately to severely active ulcerative colitis treated with Omvoh. The study showed that 63.5 percent of Omvoh-treated patients who achieved disease clearance at one year...
An outbreak of deadly hantavirus aboard a cruise ship in the Atlantic Ocean has triggered an international public health response. The World Health Organization said it is coordinating evacuations and risk assessments following the death of three people and multiple suspected infections on board ...
Filana Therapeutics Inc. (FLNA), a biotechnology company, delivered a scientific presentation outlining the biological rationale for its clinical development program for Simufilam in treating tuberous sclerosis complex-related epilepsy, at the eighteenth Eilat conference on new antiepileptic drugs and devices.